Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Editorial Board
Editor Image

Mohamad Waseem Salkini
Department of Surgery/Urology
Westi Virginia University
USA

Editor Image

Vasundara Venkateswaran
Department of Surgery
University of Toronto
Canada

Editor Image

Srinivas Vourganti
Department of Urology
State University of New York
New York

Editor Image

Dattatreyudu Nori
Department of Radiation Oncology
Weill Cornell Medical Center
New York

 

Submit Manuscript
Submit manuscript at https://www.scholarscentral.org/submission/prostate-cancer.html or send as an e-mail attachment to the Editorial Office at editor.jps@emedicalcentral.com

If you are interested in publishing with us or have any questions, please feel free to contact us directly on WhatsApp .
About the Journal

Prostate cancer is a branch of science that deals with diagnosis and treatment of cancer related to gland cells known as adenocarcinoma. Here you will find the causes, symptoms, diagnosis and treatment of prostate cancer. The journal covers up information regarding types, stages of advancement and research methodologies in prostate cancer.

Prostate cancer journal is a peer-reviewed and open access journal with an aim to provide rapid and reliable source of information on current developments in the field of oncology particularly related to prostate gland. The journal aims to publish the most complete and reliable source of information on the discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in all areas of the field and making them freely available through online without any restrictions or any other subscriptions to researchers worldwide.

Open Access Prostate cancer journal includes a wide range of fields in its discipline to create a platform for the authors to make their contribution towards the journal.

This unique platform for discussion covers the following topics broadly such as Prostate cancer, male reproductive system, Benign prostatic hyperplasia, Prostate-specific antigen, Radiation therapy, Hormone therapy, Androgen deprivation therapy, External beam radiation, Cancer prevention, Erectile dysfunction, Radical retropubic prostatectomy and Tumor suppressor gene. Focus of the high impact factor journal is the disease process explanation and organization procedures ensuring in enhanced outcomes for the patient. Patient perspective satisfaction, healthy life, quality treatment, communication and health literacy and their role in developing new health care programs and clinical outcomes are major areas of interest for this journal.

The journal is using Editorial Tracking System for quality review process. Editorial tracking system is an online manuscript submission, review and tracking systems. Review processing is performed by the editorial board members of Journal of Prostate Cancer or outside experts; at least two independent reviewer’s approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.

Submit manuscript at https://www.scholarscentral.org/submission/prostate-cancer.html or send as an e-mail attachment to the Editorial Office at editor.jps@emedicalcentral.com

Prostate Cancer

Prostate cancer is a malignancy of one of the major male sex glands. Along with the testicles and the seminal vesicles, the prostate secretes the fluid that makes up semen. The prostate is about the size of a walnut and lies just behind the urinary bladder.

Related Journals of Prostate Cancer

Journal of Nuclear Medicine & Radiation Therapy, Journal of Steroids & Hormonal Science, Journal of Cancer Science & Therapy, Journal of Molecular Biomarkers & DiagnosisThe Prostate - Wiley Online Library, Prostate Cancer and Prostatic Diseases, Prostate Cancer-An open Access Journal, Archive of Prostate Cancer, Prostate Cancer - ASCO Cancer Portals, Prostate Cancer Journal Articles - Index - Medscape.

Male Reproductive System

The male reproductive system consists of a number of sex organs that form a part of the human reproductive process. In this type of reproductive system, these sex organs are located outside the body, around the pelvic region.

Related Journals of Male Reproductive System

Journal of Prostate Cancer, Reproductive System Sexual Disorders,Journal of Andrology, Annual Reviews, Toxicologic Pathology, Nature Partner Journals.

Abiraterone Acetate

Abiraterone acetate is a type of hormone therapy, classified as an “adrenal inhibitor". It is indicated for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who have already received prior chemotherapy containing docetaxel.

Related Journals of Abiraterone Acetate

Journal of Prostate Cancer, Journal of Cancer Science & Therapy, The Lancet Oncology, Prostate Cancer Learning Hub, journal of clinical oncology, European society for medical oncology

Androgen Receptor

The androgen receptor, also known as NR3C4 is a type of nuclear receptor which is activated by binding either of the androgenic hormones, testosterone, or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. The main function is to regulate gene expression.

Related Journals of Androgen Receptor

Journal of Prostate Cancer, Journal of Cancer Science & Therapy, British journal of cancer, Hindawi Publishing Corporation, oncology times

Bicalutamide

Bicalutamide is used in combination with a luteinizing hormone releasing hormone (LHRH) analog (eg, goserelin, leuprolide) for the treatment of stage D2 metastatic prostate cancer. It has also been used in clinical trials for ovarian cancer.

Related Journals of Male Reproductive System

Journal of Prostate Cancer, Journal of Cancer Science & Therapy,  The journal of urology, Radiation oncology

Cabazitaxel

Cabazitaxel is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug and classified as a "taxane derivitive" and an "anti-microtubule agent." It is approved for treatment for treatment of patients with castrate resistant metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.

Related Journals of Cabazitaxel

Journal of Prostate Cancer, Journal of Cancer Science & Therapy, Dovepress, European Journal of Hospital Pharmacy, Indo American Journal of Pharmaceutical Research

Degarelix

Degarelix injection is used to treat advanced prostate cancer. Degarelix injection is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone produced by the body. This may slow or stop the spread of prostate cancer cells that need testosterone to grow.

Related Journals of Degarelix

Journal of Prostate Cancer, Journal of Cancer Science & Therapy, Journal of Blood & LymphJournal of hematology and oncology, Casesjournal, American journal of roentgenology

Docetaxel

Docetaxel is an anti-neoplastic chemotherapy drug, classified as a "plant alkaloid," a "taxane" and an "antimicrotubule agent." It may cause low levels of white blood cells in the blood. It can be treated for locally metastatic breast cancer, gastric cancer, hormone-refractory prostate cancer and non small-cell lung cancer.

Related Journals of Docetaxel

Journal of Prostate Cancer, Journal of Cancer Science & Therapy, The new england journal of medicine, Europeanurology

Enzalutamide

Enzalutamide is an androgen receptor inhibitor. It works by blocking the action of testosterone. It is used for the treatment of metastatic castration resistant prostate cancer. Some studies suggest that enzalutamide also inhibits breast cancer cell growth.

Related Journals of Enzalutamide

Journal of Prostate Cancer, Journal of Cancer Science & Therapy.

Lymph Node

A lymph node is an oval-shaped organ of the lymphatic system, distributed throughout the body and linked by lymphatic vessels. Lymph nodes are major sites of B, T, and other immune cells. Lymph nodes are required for the proper functioning of the immune system, which act as filters for foreign particles and cancer cells.

Related Journals of Lymp Node

Journal of Prostate Cancer, Journal of Cancer Science & Therapy, Journal of hematology and oncology, Casesjournal, American journal of roentgenology

Fast Editorial Execution and Review Process (FEE-Review Process):

Journal of Prostate Cancer is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.

Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.

The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.


 
Top